ArticleCancer cell2011
Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.
Article in Cancer cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.Nature medicine · 2019Trial
- Oncogene inactivation-induced senescence facilitates tumor relapse.Nature communications · 2026Article
- Investigating T Cell Immunity in Cancer: Achievements and Prospects.International journal of molecular sciences · 2021Review
- CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus.Cancers · 2021Article
- Longitudinal imaging of T cell-based immunotherapy with multi-spectral, multi-scale optoacoustic tomography.Scientific reports · 2020Article
- Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.The Journal of clinical investigation · 2019Article
- In situ administration of cytokine combinations induces tumor regression in mice.EBioMedicine · 2018Article
- Article
- Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity.Scientific reports · 2017Article
- Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.The Journal of experimental medicine · 2016Article
- Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.Cell death & disease · 2014Article
- An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Immunologic research · 2014Review
- Oncogene withdrawal engages the immune system to induce sustained cancer regression.Journal for immunotherapy of cancer · 2014Review
- CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.Cancer immunology research · 2013Article
- Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.Cancer cell · 2013Article
- Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.Current opinion in immunology · 2013Review
- Noncanonical roles of the immune system in eliciting oncogene addiction.Current opinion in immunology · 2013Review
- Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.The Journal of clinical investigation · 2013Article
- Fas expression by tumor stroma is required for cancer eradication.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.Frontiers in immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
The genetic instability of cancer cells frequently causes drug resistance. We established mouse cancer models, which allowed targeting of an oncogene by drug-mediated inactivation or monospecific CD8(+) effector T (T(E)) cells. Drug treatment of genetically unstable large tumors was effective but selected resistant clones in the long term. In contrast, T(E) cells completely rejected large tumors (≥500 mm(3)), if the target antigen was cancer-driving and expressed in sufficient amounts. Although drug-mediated oncogene inactivation selectively killed the cancer cells and left the tumor vasculature intact, which likely facilitated survival and growth of resistant clones, T(E) cell treatment led to blood vessel destruction and probably "bystander" elimination of escape variants, which did not require antigen cross-presentation by stromal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.